Cancer drug repurposed to fight long COVID brain fog in tiny trial

NCT ID NCT07388550

Not yet recruiting Symptom relief Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Source: ClinicalTrials.gov ↗

First seen Feb 05, 2026 · Last updated May 10, 2026 · Updated 10 times

Summary

This early-stage trial tests whether a single dose of pembrolizumab, a cancer drug, is safe for people with long COVID who have brain-related symptoms like headache, dizziness, or trouble thinking. Fifteen adults who had COVID at least 6 months ago will receive the drug and be followed for 7 months. The goal is to see if the drug can calm an overactive immune system and ease these lingering symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-ACUTE COVID-19 SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

POST-ACUTE COVID-19 SYNDROME